Evidence map›Paper›PMID 33590406›Full record

ReviewVirus genes2021

Prophylactic strategies to control chikungunya virus infection.

Friederike I L Hucke, Malena Bestehorn-Willmann, Joachim J Bugert

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Virus genes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Friederike I L HuckeBundeswehr Institute of Microbiology, Neuherbergstraße 11, 80937, München, Germany.
Malena Bestehorn-WillmannBundeswehr Institute of Microbiology, Neuherbergstraße 11, 80937, München, Germany.
Joachim J BugertBundeswehr Institute of Microbiology, Neuherbergstraße 11, 80937, München, Germany. Joachim1Bugert@bundeswehr.org.ORCID http://orcid.org/0000-0002-0556-3211
Universität der Bundeswehr München · DE

Funding

Bundeswehr IMB-59-2016-STAN
6 · The paper itself

Abstract

Chikungunya virus (CHIKV) is a (re)emerging arbovirus and the causative agent of chikungunya fever. In recent years, CHIKV was responsible for a series of outbreaks, some of which had serious economic and public health impacts in the affected regions. So far, no CHIKV-specific antiviral therapy or vaccine has been approved. This review gives a brief summary on CHIKV epidemiology, spread, infection and diagnosis. It furthermore deals with the strategies against emerging diseases, drug development and the possibilities of testing antivirals against CHIKV in vitro and in vivo. With our review, we hope to provide the latest information on CHIKV, disease manifestation, as well as on the current state of CHIKV vaccine development and post-exposure therapy.

Indexed as

Pre-Exposure ProphylaxisAnimalsAntiviral AgentsChikungunya FeverChikungunya virusDrug DevelopmentHumansViral VaccinesAntiviral AgentsViral VaccinesAntiviral designAntiviral testingCHIKV epidemiologyMonoclonal antibodiesVaccines

Identifiers

PMID33590406
PMCPMC7883954
OpenAlexW3131428924

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.